Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Kadoyama, Kaori ^a   Kuwahara, Akiko ^b   Yamamori, Motohiro ^b   Brown, J B ^a   Sakaeda, Toshiyuki ^a   Okuno, Yasushi ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c Kyoto Constella Technologies Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MERCAPTOPURINE; PACLITAXEL; PROCARBAZINE; TENIPOSIDE; TAXOID;

DISEASE SEVERITY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; REVIEW; ARTICLE; BAYES THEOREM; DATA MINING; PROGNOSIS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BAYES THEOREM; DATA MINING; DRUG HYPERSENSITIVITY; ETOPOSIDE; HUMANS; PACLITAXEL; PHARMACOVIGILANCE; PROCARBAZINE; PROGNOSIS; TAXOIDS; TENIPOSIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80053538478     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-93     Document Type: Review

References (28)

1. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Pagani M, Med Clin North Am 2010 94 835 852 10.1016/j.mcna.2010.03.002 20609866
2. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Syrigou E, Syrigos K, Saif MW, Curr Allergy Asthma Rep 2008 8 56 62 10.1007/s11882-008-0011-0 18377776 (Pubitemid 351459694)
3. Hypersensitivity reactions to chemotherapeutic drugs. Shepherd GM, Clin Rev Allergy Immunol 2003 24 253 262 10.1385/CRIAI:24:3:253 12721396 (Pubitemid 36584220)
4. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Lee C, Gianos M, Klaustermeyer WB, Ann Allergy Asthma Immunol 2009 102 179 187 10.1016/S1081-1206(10)60078-6 19354063
5. Management and preparedness for infusion and hypersensitivity reactions. Lenz HJ, Oncologist 2007 12 601 609 10.1634/theoncologist.12-5-601 17522249 (Pubitemid 350012124)
6. Adverse event profiles of platinum agents: Data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Sakaeda T, Kadoyama K, Okuno Y, Int J Med Sci 2011 8 487 491 21897761
7. Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA adverse event reporting system, AERS. Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y, Int J Med Sci 2011 8 332 338 21611115
8. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Evans SJ, Waller PC, Davis S, Pharmacoepidemiol Drug Saf 2001 10 483 486 10.1002/pds.677 11828828 (Pubitemid 34100774)
9. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC, Pharmacoepidemiol Drug Saf 2002 11 3 10 10.1002/pds.668 11998548 (Pubitemid 34269590)
10. A Bayesian neural network method for adverse drug reaction signal generation. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM, Eur J Clin Pharmacol 1998 54 315 321 10.1007/s002280050466 9696956 (Pubitemid 28328016)
11. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Szarfman A, Machado SG, O'Neill RT, Drug Saf 2002 25 381 392 10.2165/00002018-200225060-00001 12071774 (Pubitemid 34729136)
12. Quantitative signal detection using spontaneous ADR reporting. Bate A, Evans SJ, Pharmacoepidemiol Drug Saf 2009 18 427 436 10.1002/pds.1742 19358225
13. Practical pharmacovigilance analysis strategies. Gould AL, Pharmacoepidemiol Drug Saf 2003 12 559 574 10.1002/pds.771 14558179 (Pubitemid 37220642)
14. Novel statistical tools for monitoring the safety of marketed drugs. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N, Clin Pharmacol Ther 2007 82 157 166 10.1038/sj.clpt.6100258 17538548 (Pubitemid 47078877)
15. Hypersensitivity reactions to docetaxel: Retrospective evaluation and development of a desensitization protocol. Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN, Int Arch Allergy Immunol 2011 156 320 324 10.1159/000324454 21720178
16. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. Szebeni J, Muggia FM, Alving CR, J Natl Cancer Inst 1998 90 300 306 10.1093/jnci/90.4.300 9486816 (Pubitemid 28182386)
17. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y, Int Immunopharmacol 2001 1 721 735 10.1016/S1567-5769(01)00006-6 11357884 (Pubitemid 32206533)
18. Anaphylaxis following continuous 5-fluorouracil infusion chemotherapy. Biswal BM, Aust N Z J Med 1999 29 743 744 10.1111/j.1445-5994.1999.tb01627.x 10630660 (Pubitemid 29530196)
19. Allergic reaction to 5-fluorouracil infusion. Sridhar KS, Cancer 1986 58 862 864 10.1002/1097-0142(19860815)58:4<862::AID-CNCR2820580410>3.0.CO;2-3 3719553 (Pubitemid 16035284)
20. Desensitization to 5-fluorouracil. Eppinger T, Sperber K, Allergy Asthma Proc 1999 20 189 191 10.2500/108854199778553064 10389552
21. Anaphylactic reaction following i.v. administration of 5-fluorouracil. Millá Santos A, Sanchiz Medina F, Cancer Treat Rep 1986 70 1346 3768880 (Pubitemid 17184308)
22. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream). Meijer BU, de Waard-van der Spek FB, Contact Dermatitis 2007 57 58 60 10.1111/j.1600-0536.2007.01079.x 17577364 (Pubitemid 46944430)
23. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? Epstein E, J Am Acad Dermatol 1998 38 77 80 10.1016/S0190-9622(98)70542-0 9448209 (Pubitemid 28100469)
24. Allergic contact dermatitis from stearyl alcohol in Efudix cream. Yesudian PD, King CM, Contact Dermatitis 2001 45 313 314 10.1034/j.1600-0536. 2001.450521.x 11722503 (Pubitemid 33032983)
25. Allergic contact dermatitis from 5-fluorouracil with positive intradermal test and doubtful patch test reactions. Sánchez-Pérez J, Bartolomé B, del Río MJ, García-Díez A, Contact Dermatitis 1999 41 106 107 10445697 (Pubitemid 29363837)
26. The hand-foot-syndrome associated with medical tumor therapy- classification and management. Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, Gutzmer R, J Dtsch Dermatol Ges 2010 8 652 661 20482685
27. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Yen-Revollo JL, Goldberg RM, McLeod HL, Clin Cancer Res 2008 14 8 13 10.1158/1078-0432.CCR-07-1225 18172246 (Pubitemid 351377972)
28. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R, Eur J Cancer 1997 33 967 969 10.1016/S0959-8049(96)00497-2 9291822 (Pubitemid 27287052)